Choroidal neovascularization in angioid streaks following microincision vitrectomy surgery: a case report by unknown
Katagiri et al. BMC Ophthalmology 2013, 13:29
http://www.biomedcentral.com/1471-2415/13/29CASE REPORT Open AccessChoroidal neovascularization in angioid
streaks following microincision vitrectomy
surgery: a case report
Satoshi Katagiri1*, Takaaki Hayashi1, Hirotsugu Takashina2, Katsuya Mitooka2 and Hiroshi Tsuneoka1Abstract
Background: Patients with angioid streaks are prone to developing subretinal hemorrhage after ocular or
head injury due to the brittleness of Bruch’s membrane. However, there have been no reports of any angioid
streak patients in whom choroidal neovascularization occurred after vitrectomy surgery. We report herein a
patient with angioid streaks who developed choroidal neovascularization after vitrectomy surgery for epiretinal
membrane.
Case presentation: A 76-year-old man presented with distorted vision in his left eye, with a best corrected
visual acuity of 1.2 and 0.6 in his right and left eyes, respectively. Fundus examination showed angioid streaks
in both eyes and epiretinal membrane only in the left eye. The patient underwent 23-gauge three-port pars
plana vitrectomy with removal of the epiretinal membrane combined with cataract surgery. Internal limiting
membrane in addition to the epiretinal membrane were successfully peeled and removed, with indocyanine
green dye used to visualize the internal limiting membrane. His left best corrected visual acuity improved to
0.8. An elevated lesion with retinal hemorrhage due to probable choroidal neovascularization was found
between the fovea and the optic disc in the left eye at 7 weeks after surgery. Since best corrected visual
acuity decreased to 0.15 and the hemorrhage expanded, posterior sub-Tenon injection of triamcinolone
acetonide was performed. However, no improvement was observed. Even though intravitreal bevacizumab
injection was performed a total of five times, his best corrected visual acuity remained at 0.1. Subsequently,
we performed a combination treatment of a standard-fluence photodynamic therapy and intravitreal
ranibizumab injection, with additional intravitreal ranibizumab injections performed 3 times after this
combination treatment. Best corrected visual acuity improved to 0.5 and the size of the choroidal
neovascularization markedly regressed at 4 months after the combined treatment.
Conclusion: Development of choroidal neovascularization could possibly occur in elderly patients with
angioid streaks after vitrectomy surgery. In such cases, a combination of photodynamic therapy and
intravitreal ranibizumab injection may be considered for initial treatment of the choroidal neovascularization.
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Figure 1 Optical coherence tomography before surgery and
fundus photograph of patient during vitrectomy surgery. a)
Epiretinal membrane (ERM) in optic coherence tomography before
vitrectomy surgery. b) Fundus photograph during vitrectomy
surgery. The ERM is successfully peeled before ILM peeling.
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Angioid streaks (AS) are visible irregular crack-like
dehiscences radiating from the optic nerve to the per-
ipheral retina. Approximately 70% of AS patients have
pseudoxanthoma elasticum (PXE) characterized by
changes in the elastic tissue of the skin [1]. Patients with
AS are usually asymptomatic unless the lesions extend
towards the fovea or develop complications such as
traumatic Bruch’s membrane rupture or choroidal
neovascularization (CNV). Several studies on the rela-
tionship between ocular trauma and subretinal
hemorrhage in patients with AS have been reported
[2,3]. There is also a report of an AS patient who de-
veloped CNV after indirect trauma to the eye itself
[4]. It has also been reported that 15% of AS patients
who suffer head injuries develop significant visual
impairment [5]. However, to our knowledge, there
have been no reports of any AS patients in whom
CNV occurred after vitrectomy surgery.
We report herein a case of an AS patient in whom
CNV occurred at 7 weeks after microincision vitrectomy
surgery for removal of epiretinal membrane (ERM).
Case presentation
A 76-year-old male patient with a medical history of
hypertension but no eye surgery reported distorted vi-
sion in the left eye. Best corrected visual acuity (BCVA)
at his initial examination was 1.2 (with +1.75 diopter
(dpt), cylinder (cyl) -1.25 dpt Ax 110°) in his right eye
and 0.6 (with +2.75 dpt, cyl. -1.50 dpt Ax 90°) in his left
eye. Using the IOLMaster 500 (Carl Zeiss Meditec AG,
Dublin, CA, USA), his axial lengths were determined to
be 23.3 and 23.1 mm in his right and left eyes, respect-
ively. Except for mild senile cataracts in the anterior
segments and media of both of his eyes, there were no
abnormalities found. Intraocular pressures were 13
mmHg on the right and 11 mmHg on the left. Fundus
examination showed ERM in the left eye, in addition to
bilateral AS. Although spectral-domain optical coher-
ence tomography (OCT; Cirrus HD-OCT, Carl Zeiss
Meditec AG) using the high-definition 5-line raster scan
protocol (horizontal scan of 6 mm) revealed ERM, CNV
was not observed in the macula of his left eye (Figure 1a).
The patient subsequently underwent 23-gauge three-
port pars plana vitrectomy with removal of ERM com-
bined with cataract surgery at The Jikei University,
Daisan Hospital. Indocyanine green dye was used to
visualize the internal limiting membrane (ILM). The
ILM in addition to the ERM were successfully peeled
and removed (Figure 1b). No retinal hemorrhage was
noted during the vitreous surgery (Figure 1b), and his
left BCVA subsequently improved to 0.8.
Seven weeks after the vitrectomy surgery, an elevated
lesion with retinal hemorrhage due to probable CNVwas found between the fovea and the optic disc in his
left eye (Figure 2), although he had no history of any
ocular trauma after the surgery. One week later, his left
BCVA decreased to 0.15 and the retinal hemorrhage
expanded. Although posterior sub-Tenon injection of
triamcinolone acetonide was performed, no visual im-
provement was seen.
At 12 weeks after the vitrectomy surgery at The Jikei
University Hospital, his BCVA was 0.08 in his left eye.
Fundus examination revealed a radiating dark brownish
line from the optic disc head in his right (Figure 3a) and
left (Figure 3b) eyes, and there was an elevated
subretinal lesion with retinal hemorrhage in his left mac-
ula (Figure 3b). Although OCT showed no abnormal
findings in his right eye (Figure 3c), Gass type 2 CNV
with macular edema was observed in his left eye
(Figure 3d). Fluorescein angiography (FA) revealed
well-defined (classic) CNV from the early (Figure 3e)
to late phases (Figure 3f ) in the left macula. Using
indocyanine green angiography (ICGA), we were able
Figure 2 Left fundus finding 7 weeks after the vitrectomy
surgery. Photograph shows an elevated lesion with retinal
hemorrhage that is most likely due to probable choroidal
neovascularization found between the fovea and the optic disc.
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late phases (Figure 3h).
Over the next 6 months, a total of 5-time intravitreal
injections of the anti-vascular endothelial growth factor
(VEGF) drug, bevacizumab (Avastin, Genentech, San
Francisco, CA, USA), were given. His left BCVA
remained at 0.1. Fundus examination demonstrated that
there was no regression of the CNV (Figure 4a), as was
confirmed by OCT (Figure 4b). The FA images indicated
there was a foveal lesion with evidence of classic CNV in
the early phase (Figure 4c) and an extended high fluores-
cent lesion in the late phase (Figure 4d).
Subsequently, we performed standard-fluence photo-
dynamic therapy (PDT: laser fluence set at 50 J/cm2)
with full-dose verteporfin (Visudyne; Novartis Pharma
AG, Basel, Switzerland) in combination with an
intravitreal ranibizumab (Lucentis, Genentech) (IVR) in-
jection. After this combination treatment, 3 additional
IVR treatments were performed. At 4 months after the
combination treatment, his BCVA improved to 0.5.
There was a marked regression of the CNV size
observed in both the fundus (Figure 5a). OCT showed
significant but incomplete regression of CNV, and per-
sistence of intra-retinal cysts (Figure 5b). The FA images
revealed that leakage from the CNV noted in the earlyphases (Figure 5c) almost completely disappeared by the
late phases (Figure 5d).
Examination of the skin on the neck showed suggest-
ive of PXE. A skin biopsy was performed from the lesion
on the neck. The histological section of the biopsy re-
vealed short and broken elastic fibers with dark stain-
ing of calcium deposits by Von Kossa staining in the
reticular dermis (Figure 6), convincing a diagnosis of
PXE.
Discussion
In this report, we describe a single AS patient in whom
CNV developed 7 weeks after vitrectomy surgery for
ERM. To date, there have been no other reports of any
AS patients who have developed CNV after vitrectomy
surgery.
Numerous studies have reported the incidence of
CNV to vary between 72%–86% in AS patients [5]. It is
reported that the risk of developing CNV increases with
age [6]. Other risk factors comprise the width, length
and location of the AS. Several studies have reported
that wider and longer AS are associated with higher risk
of CNV, and that the risk of CNV development is espe-
cially higher if AS are located within one optic disc
diameter from the foveola [5,7,8].
As an external factor, ocular trauma can be a risk fac-
tor for the development of subretinal hemorrhage [2,3].
In fact, AS patients are likely to develop breaks of
Bruch’s membrane even after relatively mild ocular head
injuries, since their Bruch’s membrane is brittle [5]. In
addition, it has also been reported that an AS patient
developed CNV 4 months after an indirect ocular
trauma [4]. Thus, it is possible that CNV can occur due
to either direct or indirect ocular trauma.
Regarding the relationship between vitrectomy surgery
and CNV development, there have been some studies
that have reported finding CNV after vitrectomy surgery
for idiopathic macular hole [9-12]. Although the patho-
genesis underlying the development of CNV after macu-
lar hole surgery has yet to be completely clarified, it has
been suggested that the most plausible explanation is an
age-related degenerative change in the retinal pigment
epithelium (RPE) and Bruch’s membrane. This is sup-
ported by the fact that there is a higher prevalence of
CNV development after macular hole surgery in older
patients [10,13]. In addition, as has been reported in a
previous study, mechanical trauma during the ILM peel-
ing in the macular hole surgery might have played a role
in the pathogenesis of the CNV that subsequently devel-
oped in the patient [10]. In fact, this is similar to the
current case, as our patient had brittleness of Bruch’s
membrane and RPE because of AS and aging and thus,
underwent vitrectomy surgery with ERM and ILM peel-
ing, after which he developed CNV.
Figure 3 (See legend on next page.)
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Figure 3 Fundus findings prior to the initial anti-vascular endothelial growth factor therapy. a, b) Fundus photographs show angioid
streaks in the right (a) and left (b) eyes and choroidal neovascularization (CNV) in the left macula (b). c, d) Optical coherence tomography shows
no abnormal finding in the right eye (c) and Gass type 2 CNV with macular edema in the left eye (d). e, f) Fluorescein angiograms show well-
defined (classic) CNV in the early (e) to late phases (f) in the left macula. g, h) Indocyanine green angiograms show CNV is visualized from the
early (g) to late phases (h) in the left macula.
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have described the use of monotherapy treatments
employing PDT or anti-VEGF therapies. For example,
Arias et al. reported that PDT was not effective in the
treatment of CNV in the macula [14], while Browning
et al. showed that PDT delayed, but did not permanently
prevent visual loss associated with the CNV in AS [15].
However, in other cases it has been reported that in-
jection of intravitreal bevacizumab (IVB) was effective
as a long-term control tool for CNV associated with
AS [16,17]. Moreover, it has been reported that IVR
was also effective in treating CNV associated with AS
[18-20]. Even so, after the patient in the current caseFigure 4 Left fundus findings after 5 intravitreal bevacizumab injectio
choroidal neovascularization (CNV). b) Optical coherence tomography also
angiograms show evidence of classic CNV in the early (c) to the late phasereceived 5-time IVB injections, the CNV remained ac-
tive. This suggested that there was a decrease in the
biologic effect after repeated intravitreal anti-VEGF
injections of the same drug, such as bevacizumab
[21-23]. An in vitro experiment demonstrated that the
absence or presence of hyaluronan, which is a major
component in the vitreous body, may be associated
with the clinical efficacy of IVB because of the higher
affinity of hyaluronan for bevacizumab as compared
to that for ranibizumab [24]. Christoforidis et al.
revealed that clearance rates for intravitreally placed
bevacizumab or ranibizumab in vitrectomized or
lensectomized rabbit model eyes are faster than thosens. a) Fundus photograph indicates there is no regression of the
confirms there is no regression of the CNV. c, d) Fluorescein
s (d).
Figure 5 Left fundus findings 4 months after the combination treatment. a) Fundus photograph shows marked regression of the choroidal
neovascularization (CNV). b) Optical coherence tomography shows significant but incomplete regression of CNV, and persistence of intra-retinal
cysts. c, d) Fluorescein angiograms show that leakage from the CNV almost completely disappears between the early (c) and late phases (d).
Figure 6 Histological findings of a skin biopsy on the neck. The
histological section reveals short and broken elastic fibers with dark
staining of calcium deposits by Von Kossa staining in the reticular
dermis, convincing a diagnosis of pseudoxanthoma elasticum.
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in conjunction with the bevacizumab tachyphylaxis
and the vitrectomized-pseudophakic condition that
was present, we decided to use ranibizumab instead
of bevacizumab in all of the subsequent treatments
for this patient. Recently, it has been reported that
the combination of IVR and reduced-fluence PDT for
CNV associated with AS was effective in the regres-
sion of CNV and in improving (or stabilizing) the vis-
ual acuity [26,27]. Based on the above-mentioned
findings, we performed the combined therapy of full-
dose PDT and IVR instead of IVR monotherapy. Our
current results support the effectiveness of the com-
bined therapy, as the combination therapy of full-dose
PDT and IVR was effective, with improvement of the
visual acuity and regression of the CNV ultimately
seen in our patient.
Conclusions
Development of CNV can occur in elderly patients with AS
after vitrectomy surgery. In such cases, the combination of
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http://www.biomedcentral.com/1471-2415/13/29PDT and anti-VEGF therapies may be considered for use as
the initial treatment of CNV.
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